Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy
Jia Yi Tan(Saint Michael's Medical Center), Mohammad Muhsin Chisti(Beaumont Hospital, Troy), Min Choon Tan(New York Medical College), Yong Hao Yeo(Beaumont Health), Julio C. Chávez(Moffitt Cancer Center)
Cited by 1
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
|PubMed|2020|143
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
|Journal of the National Comprehensive Cancer Network|2019|94